MaxCyte

Sarah Meeks, Ph.D., VP of Business Development
Gaithersburg, MD
(LSE: MXCT)
MaxCyte is a global cell-based medicines and life sciences company applying its proprietary cell engineering technology platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte leverages its Flow Electroporation® Technology to enable its biopharmaceutical partners to advance development of innovative medicines, particularly in cell therapy, including the use of gene editing tools in treatment of genetic diseases and immuno-oncology approaches to cancer treatments. MaxCyte has placed its cutting-edge instruments worldwide, with all of the top ten global biopharmaceutical companies, and has 140+ cell therapy programs and 100+ licensed for clinical use. With its robust delivery technology platform, MaxCyte helps its biopharmaceutical industry partners to unlock the full potential of their products. www.maxcyte.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions